Page last updated: 2024-11-04

sulforaphane and Pulmonary Arterial Hypertension

sulforaphane has been researched along with Pulmonary Arterial Hypertension in 1 studies

sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.

Pulmonary Arterial Hypertension: A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.

Research Excerpts

ExcerptRelevanceReference
" We recently demonstrated that sulforaphane (SFN) protected mice from developing pulmonary arterial hypertension (PAH) and right ventricular (RV) dysfunction by elevating cardiac Nrf2 expression and function."4.12Sulforaphane Does Not Protect Right Ventricular Systolic and Diastolic Functions in Nrf2 Knockout Pulmonary Artery Hypertension Mice. ( Cai, J; Cai, L; Cathey, D; Huang, J; Kang, Y; Keller, BB; LeBlanc, AJ; Wang, S; Zhang, G, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zhang, G1
Kang, Y1
Cathey, D1
LeBlanc, AJ1
Cai, J1
Cai, L1
Wang, S1
Huang, J1
Keller, BB1

Other Studies

1 other study available for sulforaphane and Pulmonary Arterial Hypertension

ArticleYear
Sulforaphane Does Not Protect Right Ventricular Systolic and Diastolic Functions in Nrf2 Knockout Pulmonary Artery Hypertension Mice.
    Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:3

    Topics: Animals; Hypertension, Pulmonary; Isothiocyanates; Male; Mice; Mice, Knockout; NF-E2-Related Factor

2022